Study will assess the safety and effectiveness of irreversible electroporation as a minimally invasive treatment option for benign prostatic hyperplasia (BPH)
At 34 weeks, Ultomiris achieved a 43.4% placebo-adjusted reduction in 24-hour urine protein creatinine ratio (UPCR) versus placebo, meeting the study’s key interim endpoint
Libre Duo devices become the first glucose-ketone monitors approved for diabetes care, offering real-time alerts for diabetic ketoacidosis risk
The precision health platform integrates genetics, biomarkers, diet, and lifestyle data to deliver personalised gut health interventions and therapy support
IgAN is a rare, progressive kidney disease driven by abnormal IgA immune complexes that deposit in the kidneys
he innovation could pave the way for early and low-cost screening of smoking exposure and second-hand smoke biomarkers
The trial met its primary endpoint, with patients receiving povetacicept achieving a 52.0% reduction in UPCR at Week 36
The collaboration aims to combine synthetic biology with cutting-edge detection technology to create a first-of-its-kind oral pill embedded with tumor-targeting sensors
Alport Syndrome is caused by genetic mutations affecting type IV collagen in the kidneys, ears, and eyes
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
